The Implementation of a PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) Program in Portugal

Dear Editor,

Last June, Centro Hospitalar Universitário de São João started a pressurized intraperitoneal aerosol chemotherapy (PIPAC) program, having treated three patients until now.

Despite all the therapeutic advances in oncology, with remarkable survival improvements in different cancers, peritoneal metastasis (PM) continues to be a challenging field with no efficient therapeutic options, other than for a few patients with limited disease that can be candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority will have extensive disease that prevents this strategy.1

A theory that tries to explain the poor prognosis and the lack of a valid therapeutic option for PM is called the ‘plasma-peritoneal barrier’.2 This phenomenon is similar to the blood–brain barrier, in which the diffusion of systemic drugs is limited. In 2011, Marc Reymond described an experimental treatment with an optimized technology for the peritoneal delivery of aerosolized chemotherapy.3 It allows to overcome the limitation of systemic chemotherapy in terms of the drug distribution and poor penetration into peritoneal nodules, but also to improve the delivery of peritoneal chemotherapy compared to HIPEC. A PIPAC treatment consists usually of three sessions across a six-eight-week period. However, in patients with good response, the number of sessions can be extended.1

Due to the selection bias and lack of randomized trials, it is impossible to properly appraise the survival benefits of this approach. However, the results have been encouraging, with an objective tumor response according to the histological Peritoneal Regression Grading Score of around 70%4 and, in some patients, with a reduction in PM that allows subsequent cytoreduction surgery and HIPEC.1 The research around PIPAC has been focusing on optimizing the procedure as well as treatment regimen/doses to allow the development of clinical trials.

Even though the two surgeons involved in this program took part in the Scandinavian PIPAC Workshop in 2018 and 2019, the pandemic situation prevented this from happening until now. We are very pleased to have this treatment option now available for selected patients with PM from different cancers. In Denmark, all PIPAC procedures are centralized in one center, and we agree that a similar strategy should also be employed in Portugal, to allow the accrual of crucial knowledge and expertise about this treatment. We are collaborating with other PIPAC centers around the world5 and have a dedicated multidisciplinary team to evaluate candidate patients referred to our center for this new treatment approach.

AUTHORS CONTRIBUTION

TBM: Conception of the original idea; writing of the manuscript.
MA, SM, MG, EB: Revision of the manuscript.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2013.

DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients’ data publication.

COMPETING INTERESTS

The authors have declared that no competing interests exist.

FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES


Tiago BOUÇA-MACHADO1, Marisa ARAL1, Sara MEIRELES2, Martin GRAVERSEN3, Elisabete BARBOSA1

Autor correspondente: Tiago Bouça-Machado. tiago.machado@chsj.min-saude.pt

Recebido/Received: 12/07/2022 - Aceite/Accepted: 19/10/2022 - Publicado Online/Published Online: 04/11/2022

Copyright © Ordem dos Médicos 2022

https://doi.org/10.20344/amp.18834